Skip to content

Assesment safety and efficacy of Ayurvedic Formulation AYUSH AGT in external wounds.

An open label Clinical trial to evaluate clinical efficacy and safety of Ayush AGT for external wounds.

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/04/024658
Enrollment
30
Registered
2020-04-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: - Health Condition 3: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere

Interventions

Intervention1: Ayush AGT cream for External application on wound: Dose -Quantity Sufficient Dosage form -Gel based ointment Route of Administration -Topical Time of Administratio

Sponsors

Central council for Research in Ayurvedic Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: .1 Patients of either sex with age between 18 and 60 years 2 Patients with Superficial externalwounds requiring dressing 3. Solitary wound not less than 1 inches (2.5 cm) in diameter 4 Patienwilling to participate in the study for 1 month

Exclusion criteria

Exclusion criteria: 1Known allergy/hypersensitivity to any of the components of the dressing 2.Wound associated with fracture 3.Wound associated with skin disorder that is chronic or currently active like psoriasis, eczema 4.Neurological deficit at wound site 5.Hemoglobin level 6.Patients with concurrent Hepatic Dysfunction (defined as AST and/or ALT > 2 times of the upper normal limit) or Renal Dysfunction (defined as S.Creatinine > 1.2 mg/dl) 7.Known cases of Diabetes Mellitus, AIDS & other sexually transmitted diseases, Malignancy or known history of coagulopathy 8.Patients receiving immune-suppressive medication 9. Pregnancy or lactation 10.Varicose veins/Deep Vein Thrombosis 11.Wounds requiring full thickness graft 12.Patients where a reference wound cannot be treated in isolation fromother wounds. 13.H/o hypersensitivity to any of thetrial drugs or their ingredients. 14.Patient taking participationin any other clinical trial 15.Any other condition which the Investigatorthinksmay jeopardize the study.

Design outcomes

Primary

MeasureTime frame
Primary Outcome Measures Time to complete re-epithelialization (Time Frame: 4 weeks.)Timepoint: Primary Outcome Measures Time to complete re-epithelialization (Time Frame: 4 weeks.)

Secondary

MeasureTime frame
1.Incidence of wound infection (Time Frame: 4 weeks 2.Pain during dressing changes (score) [Time Frame: 2 weeks] 3.Any systemic effect after treatment CBC, blood glucose, electrolyte, hepatic and renal functions will be analyzed to find any changes. 4.Incidence of Blistering [Time Frame: 0-6 days] 5.Incidence of adverse reactionsTimepoint: 7th, 14th, 21 stand 28th days

Countries

India

Contacts

Public ContactDr Savita Gopod

Central council for Research in Ayurvedic sciences,

savitagopod18@gmail.com9177777631

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026